Are Gallstones a Side Effect of Mounjaro?

Last reviewed: July 11, 2026

Last updated: July 11, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide, a dual GLP-1 and GIP receptor agonist, has transformed weight loss treatment for millions of patients. However, emerging clinical data suggests a connection between rapid weight reduction and gallstone formation, a condition called cholelithiasis that affects up to 15% of people experiencing significant weight loss.

How Rapid Weight Loss Triggers Gallstone Formation

Gallstones develop when bile—a digestive fluid stored in the gallbladder—becomes supersaturated with cholesterol or bilirubin. During rapid weight loss, the body breaks down stored fat at an accelerated rate, releasing cholesterol into the bloodstream and bile in higher concentrations. This shift in bile composition increases the likelihood of cholesterol crystallization, which hardens into stones over weeks to months.

The risk is highest when people lose more than 3 pounds per week, which tirzepatide commonly enables. Clinical trials and real-world data show that patients taking tirzepatide lose 15–22% of body weight over 68 weeks, far exceeding the slow-and-steady pace of diet alone. This aggressive weight loss, while metabolically beneficial, creates an environment where gallstone formation becomes statistically more likely.

Tirzepatide and Gallstone Risk: What Clinical Trials Reveal

In Phase 3 trials for tirzepatide (branded as Mounjaro), gallstone-related adverse events occurred in approximately 1–2% of participants—a rate higher than placebo but not dramatically so. Importantly, most cases were asymptomatic; many patients had gallstones detected incidentally on imaging and experienced no pain or complications. Symptomatic cholelithitis requiring medical intervention was rare, appearing in fewer than 0.5% of trial subjects.

However, these trials enrolled people for only 68 weeks, and gallstone formation can continue months after weight stabilizes. Longer follow-up data from real-world clinical practice suggest that the actual incidence may be underestimated in randomized controlled trials. The risk is not unique to tirzepatide—it mirrors risks seen with other GLP-1 receptor agonists and bariatric surgery, both of which cause rapid weight loss through different mechanisms.

Genetic Factors That Increase Your Gallstone Susceptibility

Your genes influence bile acid metabolism, cholesterol transport, and inflammatory pathways that determine gallstone risk. PlexusDx's Precision Peptide Genetic Test identifies variants in genes like GIPR rs1800437 and GLP1R rs6923761 that correlate with metabolic efficiency and weight loss magnitude. A separate but complementary assessment of gallstone risk involves variants in genes controlling hepatic lipase, apolipoprotein E, and the farnesoid X receptor—all regulators of cholesterol solubility in bile.

Patients with a family history of gallstones, those over 40, women of childbearing age, and people with Native American ancestry face naturally elevated baseline risk. When tirzepatide accelerates weight loss in someone already predisposed, the odds compound. PlexusDx recommends discussing genetic predisposition with your provider before starting any GLP-1 therapy, ensuring informed consent and appropriate monitoring.

Monitoring and Prevention Strategies While on Tirzepatide

If you choose tirzepatide therapy through PlexusDx, proactive monitoring reduces gallstone complications. Your provider may recommend baseline ultrasound imaging if you have risk factors, followed by clinical follow-up if symptoms emerge—abdominal pain in the upper right quadrant, nausea, or pain between the shoulder blades after fatty meals. Some clinicians advise ursodeoxycholic acid supplementation during rapid weight loss phases to reduce stone formation risk, though evidence is mixed.

PlexusDx's compounded tirzepatide injection (starting at $289/mo (or $249/mo on the 6-month plan) across all commitment tiers) is dosed gradually, allowing your body to adapt metabolically. This stepwise titration approach—where your dose increases but your price stays flat—may help stabilize bile chemistry better than rapid escalation. Maintaining hydration, spreading weight loss over longer timelines when medically appropriate, and avoiding very low-fat diets can also lower cholelithiasis incidence during GLP-1 therapy.

PlexusDx Personalization: Choosing the Right GLP-1 for Your Risk Profile

Not all GLP-1 therapies carry identical gallstone risk. Semaglutide, PlexusDx's compounded semaglutide injection (starting at $189/mo (or $149/mo on the 6-month plan)), typically produces slower, more gradual weight loss than tirzepatide. For patients with genetic or clinical risk factors for cholelithiasis, slower weight loss may translate to lower stone formation rates. PlexusDx offers both options, allowing your healthcare provider to select the compound that balances efficacy with your individual safety profile.

The Precision Peptide Genetic Test ($99 add-on after your first treatment month) maps 14 metabolic pathways and 49 peptides, revealing your unique response to different GLP-1 agents. This genetic insight helps your PlexusDx provider recommend whether tirzepatide's dual-receptor power is appropriate for you, or whether a single-receptor agent like semaglutide aligns better with your genetics and gallstone risk. All medications come from licensed 503A compounding pharmacies, require no insurance, and are HSA/FSA eligible nationwide.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can tirzepatide cause gallstones?

Tirzepatide itself doesn't directly cause gallstones, but the rapid weight loss it enables can accelerate cholesterol saturation in bile, increasing formation risk. Clinical trials show gallstone-related events in 1–2% of patients, though most were asymptomatic. PlexusDx providers can monitor you closely and adjust dosing strategy if needed.

What percentage of people on tirzepatide develop gallstones?

Approximately 1–2% of clinical trial participants reported gallstone-related adverse events, compared to baseline rates of 0.5–1% in non-weight-loss populations. Symptomatic cases requiring intervention occurred in fewer than 0.5% of trial subjects. Real-world incidence may differ based on rate of weight loss and individual genetic factors.

How does PlexusDx pricing work for tirzepatide?

PlexusDx offers compounded tirzepatide injection starting at $289/mo (or $249/mo on the 6-month plan)—flat across all commitment tiers. Your dose may increase over time, but your price won't, removing the concern that stronger therapeutic doses will cost more. The service is available nationwide without insurance, and HSA/FSA accounts cover the cost.

What symptoms should I watch for if I'm on tirzepatide?

Contact your provider if you experience sharp pain in the upper right abdomen, pain between the shoulder blades after eating fatty foods, persistent nausea, or yellowing of skin or eyes. These may indicate gallstones or bile duct problems. Most tirzepatide users remain symptom-free, but early detection protects your health.

How does the Precision Peptide Genetic Test help with gallstone risk?

The test identifies your genetic variants in metabolic pathways (including GIPR rs1800437 and GLP1R rs6923761) that influence weight loss speed and bile chemistry. This insight helps your PlexusDx provider choose whether tirzepatide's aggressive weight loss or semaglutide's gentler approach aligns with your gallstone predisposition, enabling truly personalized therapy.

Related Reading

• Mounjaro Side Effects Plexusdx
• Mounjaro Side Effects
• Hers Mounjaro
• Hims Mounjaro

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.